title: Consumption of vitamin D-and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture.
abstract: The prevention of increased bone remodeling in postmenopausal women at low 10-y risk of osteoporotic fractures essentially relies on reinforcement of environmental factors known to positively influence bone health, among which nutrition plays an important role. In institutionalized women in their mid-eighties, we previously found that consumption of fortified soft plain cheese increased vitamin D, calcium, and protein intakes, reduced bone resorption biochemical markers, particularly the serum bone specific acid phosphatase tartrate resistant acid phosphatase, isoform 5b (TRAP 5b) that reflects osteoclast activity, and stimulated the serum bone anabolic factor insulin-like growth factor-I (IGF-I). Whether these effects occur in much younger women was tested in a prospective control study. Seventy-one healthy postmenopausal women aged 56.6 ± 3.9 y (mean ± SD) with low spontaneous supply of both Ca and vitamin D were randomized to consume daily (treated, n = 36) or not (controls, n = 35) two servings (2 × 100 g) of skimmed-milk, soft plain cheese for 6 wk. The vitamin D and Ca-fortified dairy product provided daily: 661 kJ, 2.5 μg vitamin D, 400 mg calcium, and 13.8 g protein. At the end of the intervention, the decrease in TRAP 5b and the increase in IGF-I were greater in the treated than in the control group (P < 0.02). The changes in serum carboxy terminal crosslinked telopeptide of type I collagen did not differ significantly between the two groups. In conclusion, like in elderly women, consumption by healthy postmenopausal women of a vitamin D and calcium-fortified dairy product that also increases the protein intake, reduces the serum concentration of the bone resorption biomarker TRAP 5b. This response, combined with the increase in serum IGF-I, is compatible with a nutrition-induced reduction in postmenopausal bone loss rate.
authors.affiliation: Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center for Osteoporosis Prevention, Geneva, Switzerland. jean-philippe.bonjour@unige.ch
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Bonjour
authors.forename: Valérie
authors.initials: V
authors.lastname: Benoit
authors.forename: Brigitte
authors.initials: B
authors.lastname: Rousseau
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Souberbielle
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000178:diet therapy / Q000503:physiopathology; D002136:Calcium, Dietary / Q000008:administration & dosage* / Q000627:therapeutic use; D002611:Cheese / Q000032:analysis; D004032:Diet / Q000009:adverse effects; D018752:Diet, Fat-Restricted; D015536:Down-Regulation; D005260:Female; D005527:Food, Fortified / Q000032:analysis; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007527:Isoenzymes / Q000097:blood*; D008875:Middle Aged; D010010:Osteoclasts / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000178:diet therapy / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000097:blood* / Q000209:etiology / Q000517:prevention & control; D017698:Postmenopause; D012306:Risk; D000071681:Tartrate-Resistant Acid Phosphatase; D014807:Vitamin D / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D002136:Calcium, Dietary; D007527:Isoenzymes; D014807:Vitamin D; D007334:Insulin-Like Growth Factor I; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase